Carlsbad, United States
CB Therapeutics, founded in 2015 and headquartered in the United States, is at the forefront of biotechnology innovation. Specializing in high-value molecules and rare ingredients, their proprietary SynBio platforms leverage synthetic genomics and bio-engineering to produce complex compounds using yeast, bacteria, and cell-free systems.
The company emphasizes sustainable and efficient production, delivering compounds like tryptamines and cannabinoids with unmatched purity and yield. By focusing on neuroscience, CB Therapeutics aims to address critical mental health and societal challenges through advanced therapeutics.
Their progress in the Health and Wellness sector was marked by a Series A investment on 04 January 2023, demonstrating investor confidence in their technological capabilities and market potential. With a commitment to sustainability and innovation, CB Therapeutics is positioned to lead in the biotech landscape.
